Efficacy and safety of ethylmethylhydroxypyridine succinate in patients with chronic cerebral ischemia

M.V. Zhuravleva

I.M. Sechenov First Moscow State Medical University (Sechenov University);
Scientific Centre of Medical Application Expertise of the Ministry of the Healthcare of the Russian Federation

ORCID: 0000-0002-9198-8661

A.B. Prokofiev

Scientific Center for Examination of Medical Devices;
Sechenov First Moscow State Medical University

S.Yu. Serebrova

Scientific Center for Examination of Medical Devices;
Sechenov First Moscow State Medical University

N.S. Vasyukova

Federal Scientific Center-all-Russian Research Skriabin and Kovalenko Institute of Experimental Veterinary Medicine the Russian Academy of Sciences

E.Yu. Demchenkova

Scientific Center for Examination of Medical Devices

V.V. Arkhipov

Scientific Center for Examination of Medical Devices

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2020;120(6): 119–124

Efficacy and safety of ethylmethylhydroxypyridine succinate in patients with chronic cerebral ischemia

Authors:

M.V. Zhuravleva, A.B. Prokofiev, S.Yu. Serebrova, N.S. Vasyukova, E.Yu. Demchenkova, V.V. Arkhipov

More about the authors

DOI: 10.17116/jnevro2020120061119

Read: 6396 times

Open to cite this article

Zhuravleva MV, Prokofiev AB, Serebrova SYu, Vasyukova NS, Demchenkova EYu, Arkhipov VV. Efficacy and safety of ethylmethylhydroxypyridine succinate in patients with chronic cerebral ischemia. S.S. Korsakov Journal of Neurology and Psychiatry. 2020;120(6):119‑124. (In Russ., In Engl.).
https://doi.org/10.17116/jnevro2020120061119

Close metadata

Recommended articles:

Modern aspects of diagnostic and therapeutic approaches in the management of patients with recurrent anogenital warts. Russian Journal of Clinical Dermatology and Venereology. 2025;(5):658-665

Current aspects of the relationship between depression and cognitive impairment in patients with Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(10):66-74

Improving the quality of life and the possibility of pathogenetic therapy in adult patients with cerebral palsy. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(10):75-84

Perceptions of the disease and self-assessment of the quality of life in patients with Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(11-2):24-31

Higher-level ambulation disorders in Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(11-2):32-38

Cognitive dysfunction in children with nervous system diseases: modern approaches to diagnosis and treatment. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(10-2):69-79

Modern treatment of patients with cervical cancer. Russian Bulletin of Obstetrician-Gynecologist. 2025;(6):29-36

Auditory dysfunction in Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(11):11-18

Features of arterial hypertension in individuals with anxiety disorders. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(11):44-51

Brain aging: molecular targets of geroprotection and prevention strategies. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(11):132-139

Chronic cerebral ischemia (CCI) is a common cerebrovascular syndrome, the development of which is associated with a high risk of increasing cognitive, behavioral, and motor disorders, and the formation of a patient’s dependence on others. Timely start of treatment can slow down the course of the disease, make it more favorable. The review considers the possibility of using the domestic neuroprotector mexidol in patients with CCI. The results of a series of clinical studies on the use of ethylmethylhydroxypyridine succinate (mexidol) in patients with CCI are analyzed. The effectiveness of the drug in relieving cognitive, affective and motor disorders is noted. Information about the good tolerance of mexidol is presented.

Keywords:

chronic brain ischemia

cognitive disorders

affective disorders

ethylmethylhydroxypyridine succinate

Mexidol

treatment

Authors:

M.V. Zhuravleva

I.M. Sechenov First Moscow State Medical University (Sechenov University);
Scientific Centre of Medical Application Expertise of the Ministry of the Healthcare of the Russian Federation

ORCID: 0000-0002-9198-8661

A.B. Prokofiev

Scientific Center for Examination of Medical Devices;
Sechenov First Moscow State Medical University

S.Yu. Serebrova

Scientific Center for Examination of Medical Devices;
Sechenov First Moscow State Medical University

N.S. Vasyukova

Federal Scientific Center-all-Russian Research Skriabin and Kovalenko Institute of Experimental Veterinary Medicine the Russian Academy of Sciences

E.Yu. Demchenkova

Scientific Center for Examination of Medical Devices

V.V. Arkhipov

Scientific Center for Examination of Medical Devices

Received:

18.05.2020

Accepted:

19.05.2020

List of references:

Kamchatnov PR, Chugunov AV, Tyazhel’nikov AA, Pyshkina LI. Patogenez hronicheskih rasstrojstv mozgovogo krovoobrashcheniya. Zhurnal Nevrologii i Psihiatrii im. S.S. Korsakova. 2017;117(12):70-77. (In Russ.). https://doi.org/10.17116/jnevro201711712270-77
Pyshkina LI, Abieva AR, Kamchatnov PR, Yasamanova AN, Kabanov AA, Darvish NA, Tyazhel’nikov AA, Silina EV, Shurygin SN. Techenie cerebrovaskulyarnoj patologii u bol’nyh so stenoziruyushchim porazheniem sonnyh arterij. Zhurnal Nevrologii i Psihiatrii im. S.S. Korsakova. 2018;9(2):24-29. (In Russ.). https://doi.org/10.17116/jnevro20181180928
Karpikova NI, Peteryuhina AA. Primenenie preparata Meksidol dlya lecheniya bol’nyh s zabolevaniyami sosudov golovnogo mozga. Byulleten’ Eksperimental’noj Biologii i Mediciny. 2006;1:32-37. (In Russ.).
Shchul’kin AV. Sovremennye predstavleniya ob antigipoksicheskom i antioksidantnom effektah meksidola. Zhurnal Nevrologii i Psihiatrii im. S.S. Korsakova. 2018;118(12):87-93. (In Russ.). https://doi.org/10.17116/jnevro201811812287
Shalashova ML, Dudaeva NG, Golovacheva TV. Primenenie Meksidola v kombinirovannoj terapii s tradicionnymi antigipertenzivnymi sredstvami u bol’nyh arterial’noj gipertenziej s priznakami hronicheskoj cerebral’no-sosudistoj nedostatochnosti. Byulleten’ Eksperimental’noj Biologii i Mediciny. 2006;1:152-155. (In Russ.).
Semchenko LN, Drozdova TV, Zinov’eva MN. Primenenie preparata Meksidol dlya lecheniya bol’nyh s hronicheskoj cerebrovaskulyarnoj nedostatochnost’yu s vestibulokohlearnymi proyavleniyami. Byulleten’ Eksperimental’noj Biologii i Mediciny. 2006;1:75-79. (In Russ.).
Abramenko YuV. Ocenka klinicheskoj effektivnosti, vazoaktivnogo i metabolicheskogo effektov meksidola u pacientov pozhilogo vozrasta s discirkulyatornoj encefalopatiej. Zhurnal Nevrologii i Psihiatrii im. S.S. Korsakova. 2011;111(11):35-41. (In Russ.).
Smirnova IN, Fyodorova TN, Tanashyan MM, Suslina ZA. Klinicheskaya effektivnost’ i antioksidantnaya aktivnost’ Meksidola pri hronicheskih cerebrovaskulyarnyh zabolevaniyah. Atmosfera. Nervnye Bolezni. 2006;1:33-36. (In Russ.).
Shetekauri SA. Sovremennye vozmozhnosti antioksidantnoj terapii i opyt lecheniya Meksidolom bol’nyh s hronicheskoj cerebrovaskulyarnoj nedostatochnost’yu. Byulleten’ Eksperimental’noj Biologii i Mediciny. 2006;1:156-159. (In Russ.).
Duma SN. Lechenie golovokruzheniya u pozhilyh pacientov s hronicheskoj cerebrovaskulyarnoj patologiej. Nevrologiya, Nejropsihiatriya, Psihosomatika. 2018;10(1):55-59. (In Russ.). https://doi.org/10.14412/2074-2711-2018-1-55-59
Chukanova EI, Chukanova AS, Mamaeva HI. Rezul’taty issledovaniya effektivnosti i bezopasnosti primeneniya meksidola u pacientov s hronicheskoj ishemiej mozga. Zhurnal Nevrologii i Psihiatrii im. S.S. Korsakova. 2015;115(2):71-74. (In Russ.). https://doi.org/10.17116/jnevro20151152171-74
Tanashyan MM, Lagoda OV, Antonova KV. Hronicheskie cerebrovaskulyarnye zabolevaniya na fone metabolicheskogo sindroma: novye podhody k lecheniyu. Zhurnal Nevrologii i Psihiatrii im. S.S. Korsakova. 2012;112:11:21-26. (In Russ.). https://doi.org/10.17116/jnevro201611691106-110
Bolotova EV, Lushpaj TYu, Kovrigina IV. Povyshenie effektivnosti lecheniya gipertonicheskoj encefalopatii preparatom meksidol. Zhurnal Nevrologii i Psihiatrii im. S.S. Korsakova. 2018;118:4:61-64. (In Russ.). https://doi.org/10.17116/jnevro20181184161-64
Yanishevskij SN. Opyt primeneniya preparata meksidol v lechenii hronicheskoj nedostatochnosti mozgovogo krovoobrashcheniya u pacientov so stenoziruyushche-okklyuziruyushchim porazheniem magistral’nyh brahicefal’nyh sosudov. Byulleten’ Eksperimental’noj biologii i Mediciny. 2006;1:159-163. (In Russ.).
Antipenko EA, Deryugina AV, Gustov AV. Sistemnoe stresslimitiruyushchee dejstvie meksidola pri hronicheskoj ishemii golovnogo mozga. Zhurnal Nevrologii i Psihiatrii im. S.S. Korsakova. 2016;116:4:28-31. (In Russ.). https://doi.org/10.17116/jnevro20161164128-31
Chukanova EI, Chukanova AS. Efficacy and safety of the drug mexidol FORTE 250 as part of sequential therapy in patients with chronic ischemia of the brain. S.S. Korsakov Journal of Neurology and Psychiatry = Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2019;119(9):1-15. (In Russ.). https://doi.org/10.17116/jnevro201911909139